← Leaderboards
Thomas H Large
Blue Oak Pharmaceuticals, Inc.
$3,883,666
Attributed
$3,883,666
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,883,666 · 2
By mechanism
R44$2,984,866 · 1
R43$898,800 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Ex Vivo Imaging”
- Rebecca R Pompano · University Of Virginia$5,429,783
- Zhengxin Cai · Yale University$5,266,135
- Melanie Koenigshoff · University Of Pittsburgh At Pittsburgh$5,239,478
- Sai Muralidhar Padala · Emory University$5,190,531
- George R Schade · University Of Washington$4,988,960
- Cam Ha Thai Tran · University Of Nevada Reno$4,772,735
Research focus
Ex Vivo ImagingFutureCustomExcretory FunctionElectroencephalographyEconomic BurdenAbsorptionCommercializationDoseDrug DevelopmentAmericanBehavioralAdultDrug DiscoveryBiological MarkersBipolar DepressionBipolar DisorderClinical ResearchAffectDesignClinical CandidateChemistryBusinessesIndustry
Grant awards (5)
Next generation drugs for bipolar depression and maintenance$329,968
R44 · FY2023 · MH · contact PI
Next generation drugs for bipolar depression and maintenance$1,229,010
R44 · FY2022 · MH · contact PI
Next generation drugs for bipolar depression and maintenance$1,425,888
R44 · FY2021 · MH · contact PI
Next Generation Drugs for Bipolar Depression and Maintenance$449,400
R43 · FY2019 · MH · contact PI
Next Generation Drugs for Bipolar Depression and Maintenance$449,400
R43 · FY2018 · MH · contact PI